MJ
McKew John C.
Directeur Scientifique
OtherM
Insider track record
ExecutiveNot enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the detailed record of transactions filed by McKew John C., Directeur Scientifique. Insider active across 2 companies, notably LUMOS PHARMA, INC.. Aggregated, 18 reports have been recorded. Split: 0 buy · 5 sells. Total volume traded: €51k. Activity tracked since 1 August 2021. The latest transaction was disclosed on 6 August 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations18 total
13,153 sharesCommon StockSEC:0001126234-24-000120:0
3,407 shares@ US$1.8866.7% of flowCommon StockSEC:0001126234-24-000094:0
1,593 shares@ US$1.793.0% of flowCommon StockSEC:0001126234-24-000091:0
2,000 shares@ US$2.846.0% of flowCommon StockSEC:0001126234-24-000036:0
438 shares@ US$3.0321.4% of flowCommon StockSEC:0001126234-24-000018:0
366 shares@ US$3.011.2% of flowCommon StockSEC:0001126234-24-000016:0
1,593 shares@ US$3.285.4% of flowCommon StockSEC:0001126234-23-000085:0
1,036 shares@ US$3.313.6% of flowCommon StockSEC:0001126234-23-000051:0
2,000 shares@ US$3.527.4% of flowCommon StockSEC:0001126234-23-000016:0
1,593 shares@ US$8.1714.5% of flowCommon StockSEC:0001126234-22-000072:0
169 shares@ US$7.622.7% of flowCommon StockSEC:0001126234-22-000068:0
1,036 shares@ US$9.2319.5% of flowCommon StockSEC:0001126234-22-000034:0
1,500 shares@ US$10.0230.1% of flowCommon StockSEC:0001126234-22-000010:0
1,500 shares@ US$10.0238.7% of flowCommon StockSEC:0001126234-22-000010
2,214 shares@ US$11.3061.3% of flowCommon StockSEC:0001126234-21-000142
2,214 shares@ US$11.3047.7% of flowCommon StockSEC:0001126234-21-000142:0
20,000 shares0Common StockSEC:0001126234-21-000102
20,000 shares0Common StockSEC:0001126234-21-000102:0
About McKew John C.
John C. McKew is the Chief Scientific Officer at Lumos Pharma, Inc. He is responsible for leading research and development of new products. John brings deep scientific expertise and plays a key role in innovation and advancing the company's research projects.